Study Stopped
Study halted prematurely as investigator left the institution.
Tranexamic Acid Study
Randomized Placebo Controlled Study Using Tranexamic Acid in Revision Total Hip Arthroplasty
1 other identifier
interventional
N/A
1 country
1
Brief Summary
The purpose of this study is to determine if tranexamic acid significantly reduces blood loss and blood transfusion in revision total hip replacement. Tranexamic acid is a drug that helps to reduce blood loss during surgery. Revision total hip replacement surgery is treatment for patients who have previously had hipe replacement surgery which failed and must be repaired/replaced.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Feb 2005
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 1, 2005
CompletedFirst Submitted
Initial submission to the registry
September 11, 2006
CompletedFirst Posted
Study publicly available on registry
September 13, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2008
CompletedOctober 5, 2015
October 1, 2015
2.9 years
September 11, 2006
October 2, 2015
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Introperative blood loss
Total blood loss
Number of blood transfusions required
Secondary Outcomes (1)
Length of acute hospital stay
Interventions
Eligibility Criteria
You may qualify if:
- Failed primary total hip arthroplasty (femoral stem, acetabular component, or both)
- years of age
You may not qualify if:
- Prosthetic infection
- Primary total hip arthroplasty
- Prisoners
- Pregnancy
- Previous adverse reaction to tranexamic acid
- Bleeding/coagulation disorders
- Renal insufficiency (serum creatinine\>two standard deviations for age)
- History of deep venous thrombosis or pulmonary embolism
- Religious beliefs/practices prohibiting blood transfusions
- Wards of the state
- Cognitively impaired patients
- Terminally ill patients
- Students and/or employees
- Color blindness
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Texas Tech University Health Sciences Center Department of Orthopaedic Surgery
Lubbock, Texas, 79430, United States
Related Publications (20)
Benoni G, Lethagen S, Nilsson P, Fredin H. Tranexamic acid, given at the end of the operation, does not reduce postoperative blood loss in hip arthroplasty. Acta Orthop Scand. 2000 Jun;71(3):250-4. doi: 10.1080/000164700317411834.
PMID: 10919295BACKGROUNDBenoni G, Fredin H, Knebel R, Nilsson P. Blood conservation with tranexamic acid in total hip arthroplasty: a randomized, double-blind study in 40 primary operations. Acta Orthop Scand. 2001 Oct;72(5):442-8. doi: 10.1080/000164701753532754.
PMID: 11728069BACKGROUNDD'Ambrosio A, Borghi B, Damato A, D'Amato G, Antonacci D, Valeri F. Reducing perioperative blood loss in patients undergoing total hip arthroplasty. Int J Artif Organs. 1999 Jan;22(1):47-51.
PMID: 10098585BACKGROUNDEkback G, Axelsson K, Ryttberg L, Edlund B, Kjellberg J, Weckstrom J, Carlsson O, Schott U. Tranexamic acid reduces blood loss in total hip replacement surgery. Anesth Analg. 2000 Nov;91(5):1124-30. doi: 10.1097/00000539-200011000-00014.
PMID: 11049894BACKGROUNDGarneti N, Field J. Bone bleeding during total hip arthroplasty after administration of tranexamic acid. J Arthroplasty. 2004 Jun;19(4):488-92. doi: 10.1016/j.arth.2003.12.073.
PMID: 15188109BACKGROUNDHayes A, Murphy DB, McCarroll M. The efficacy of single-dose aprotinin 2 million KIU in reducing blood loss and its impact on the incidence of deep venous thrombosis in patients undergoing total hip replacement surgery. J Clin Anesth. 1996 Aug;8(5):357-60. doi: 10.1016/0952-8180(96)00080-3.
PMID: 8832445BACKGROUNDHiippala ST, Strid LJ, Wennerstrand MI, Arvela JV, Niemela HM, Mantyla SK, Kuisma RP, Ylinen JE. Tranexamic acid radically decreases blood loss and transfusions associated with total knee arthroplasty. Anesth Analg. 1997 Apr;84(4):839-44. doi: 10.1097/00000539-199704000-00026.
PMID: 9085968BACKGROUNDHo KM, Ismail H. Use of intravenous tranexamic acid to reduce allogeneic blood transfusion in total hip and knee arthroplasty: a meta-analysis. Anaesth Intensive Care. 2003 Oct;31(5):529-37. doi: 10.1177/0310057X0303100507.
PMID: 14601276BACKGROUNDHusted H, Blond L, Sonne-Holm S, Holm G, Jacobsen TW, Gebuhr P. Tranexamic acid reduces blood loss and blood transfusions in primary total hip arthroplasty: a prospective randomized double-blind study in 40 patients. Acta Orthop Scand. 2003 Dec;74(6):665-9. doi: 10.1080/00016470310018171.
PMID: 14763696BACKGROUNDIdo K, Neo M, Asada Y, Kondo K, Morita T, Sakamoto T, Hayashi R, Kuriyama S. Reduction of blood loss using tranexamic acid in total knee and hip arthroplasties. Arch Orthop Trauma Surg. 2000;120(9):518-20. doi: 10.1007/s004029900132.
PMID: 11011672BACKGROUNDJanssens M, Joris J, David JL, Lemaire R, Lamy M. High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesthesiology. 1994 Jan;80(1):23-9. doi: 10.1097/00000542-199401000-00007.
PMID: 7507304BACKGROUNDJeserschek R, Clar H, Aigner C, Rehak P, Primus B, Windhager R. Reduction of blood loss using high-dose aprotinin in major orthopaedic surgery: a prospective, double-blind, randomised and placebo-controlled study. J Bone Joint Surg Br. 2003 Mar;85(2):174-7. doi: 10.1302/0301-620x.85b2.13303.
PMID: 12678347BACKGROUNDKasper SM, Elsner F, Hilgers D, Grond S, Rutt J. A retrospective study of the effects of small-dose aprotinin on blood loss and transfusion needs during total hip arthroplasty. Eur J Anaesthesiol. 1998 Nov;15(6):669-75. doi: 10.1097/00003643-199811000-00008.
PMID: 9884852BACKGROUNDLangdown AJ, Field J, Grote J, Himayat H. Aprotinin (Trasylol) does not reduce bleeding in primary total hip arthroplasty. J Arthroplasty. 2000 Dec;15(8):1009-12. doi: 10.1054/arth.2000.8102.
PMID: 11112196BACKGROUNDLemay E, Guay J, Cote C, Roy A. Tranexamic acid reduces the need for allogenic red blood cell transfusions in patients undergoing total hip replacement. Can J Anaesth. 2004 Jan;51(1):31-7. doi: 10.1007/BF03018543.
PMID: 14709457BACKGROUNDMurkin JM, Shannon NA, Bourne RB, Rorabeck CH, Cruickshank M, Wyile G. Aprotinin decreases blood loss in patients undergoing revision or bilateral total hip arthroplasty. Anesth Analg. 1995 Feb;80(2):343-8. doi: 10.1097/00000539-199502000-00023.
PMID: 7529467BACKGROUNDMurkin JM, Haig GM, Beer KJ, Cicutti N, McCutchen J, Comunale ME, Hall R, Ruzicka BB. Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am. 2000 May;82(5):675-84. doi: 10.2106/00004623-200005000-00008.
PMID: 10819278BACKGROUNDTanaka N, Sakahashi H, Sato E, Hirose K, Ishima T, Ishii S. Timing of the administration of tranexamic acid for maximum reduction in blood loss in arthroplasty of the knee. J Bone Joint Surg Br. 2001 Jul;83(5):702-5. doi: 10.1302/0301-620x.83b5.11745.
PMID: 11476309BACKGROUNDWalsh TS, McClelland DB. When should we transfuse critically ill and perioperative patients with known coronary artery disease? Br J Anaesth. 2003 Jun;90(6):719-22. doi: 10.1093/bja/aeg109. No abstract available.
PMID: 12765883BACKGROUNDYamasaki S, Masuhara K, Fuji T. Tranexamic acid reduces blood loss after cementless total hip arthroplasty-prospective randomized study in 40 cases. Int Orthop. 2004 Apr;28(2):69-73. doi: 10.1007/s00264-003-0511-4. Epub 2003 Oct 10.
PMID: 15224162BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alexander D Rosenstein, MD
Texas Tech University Health Sciences Center Department of Orthopaedic Surgery
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- DOUBLE
- Purpose
- TREATMENT
- Intervention Model
- FACTORIAL
- Sponsor Type
- OTHER
Study Record Dates
First Submitted
September 11, 2006
First Posted
September 13, 2006
Study Start
February 1, 2005
Primary Completion
January 1, 2008
Study Completion
January 1, 2008
Last Updated
October 5, 2015
Record last verified: 2015-10